Coherus Biosciences (CHRS) PT Lowered to $25 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St slips as Middle East uncertainty lifts oil; Trump-Xi talks in focus
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Wall Street ends down as oil prices, Treasury yields rise
Coherus Biosciences (CHRS) PT Lowered to $38 at BMO Capital; 'Refiling of Neulasta Biosimilar Remains on Track for 4Q17'
August 8, 2017 9:07 AM EDTBMO Capital lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $38.00 (from $43.00) while maintaining a Outperform rating, following the company's second quarter earnings report.
Analyst M. Ian Somaiya comments, "Coherus reported 2Q17 earnings and indicated progress towards addressing issues raised... More
